Novavax shares soared 24.4% to hit a new 52-week high after the biotech reported fourth-quarter 2025 revenue of $147 million, crushing Wall Street estimates of $90 million by 63%. The company swung to a net profit of $18 million from a loss of $81 million a year earlier, marking a pivotal shift in its financial trajectory.
The turnaround is powered by two major deals: a $225 million milestone from Sanofi and a $530 million non-exclusive licensing agreement with Pfizer for Novavax's Matrix-M adjuvant technology signed in January 2026. Pfizer will use the adjuvant across up to two disease areas, with $30 million upfront and up to $500 million in additional milestones. Novavax raised its 2026 adjusted revenue guidance to $230-270 million, up sharply from its prior $185-205 million forecast.
The stock is now up 56% year-to-date. Analysts see the Matrix-M platform as a game-changer that validates Novavax's pivot from a COVID-focused vaccine maker to a broader biotech licensing powerhouse.